PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
Jake S. O’Donnell(The University of Queensland), Mario Mandalà(University of Perugia), Michele W.L. Teng(University of Queensland), Daniela Massi(University of Florence)
Cited by 366
Related Papers
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
|Nature Immunology|2017|639
The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway
|Archives of Pathology & Laboratory Medicine|2020|485
<i>BRAF/NRAS</i> Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
|Journal of Clinical Oncology|2012|460
WHO classification of skin tumours
|IARC eBooks|2018|422